TC
VTGN icon

Truvestments Capital’s VistaGen Therapeutics VTGN Stock Holding History

Truvestments Capital’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.51K Sell
15,540
-1,452
-9% -$876 ﹤0.01% 955
2026
Q1 		$9.71K Hold
16,992
– – ﹤0.01% 765
2025
Q4 		$11.2K Buy
16,992
+8,337
+96% +$30.1K ﹤0.01% 682
2025
Q3 		$30.7K Buy
8,655
+1,500
+21% +$4.48K 0.01% 516
2025
Q2 		$14.3K Buy
+7,155
New +$16.3K ﹤0.01% 597

Other funds holding VTGN

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CWS
Confluence Wealth Services Mcmurray, Pennsylvania $3.5B AUM 22.08% 1-Year Est. Return

Truvestments Capital's VTGN Position: Q2 2026 in Review

Truvestments Capital reduced its VistaGen Therapeutics (VTGN) stake by 8.5% in Q2 2026, selling an estimated $876 and leaving 15,540 shares worth $3.51K. The position accounts for ﹤0.01% of the portfolio, ranked #955.

Truvestments Capital first reported a position in VTGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $30.7K in Q3 2025. 26 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Truvestments Capital held 15,540 shares of VistaGen Therapeutics worth $3.51K as of Q2 2026.
  • Truvestments Capital sold 1,452 VistaGen Therapeutics shares in Q2 2026, an estimated $876.
  • VistaGen Therapeutics made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #955 holding.
  • Truvestments Capital first reported a position in VistaGen Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Truvestments Capital's VistaGen Therapeutics position peaked at $30.7K in Q3 2025.
  • 26 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.